Staphylococcal protein A - Protalex

Drug Profile

Staphylococcal protein A - Protalex

Alternative Names: PRTX-001; PRTX-100

Latest Information Update: 11 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protalex
  • Class Antirheumatics; Bacterial proteins; Immunotherapies
  • Mechanism of Action B cell inhibitors; Immunomodulators; Macrophage inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Immune thrombocytopenic purpura; Rheumatoid arthritis
  • Phase I Autoimmune disorders
  • Preclinical Myasthenia gravis

Most Recent Events

  • 07 Jun 2017 Preclinical trials in Myasthenia gravis in USA (IV)
  • 13 Mar 2017 Protalex files for patent protection for Staphylococcal protein A for composition claims in Hong Kong
  • 13 Mar 2017 Protalex has patents pending for Staphylococcal protein A in Europe and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top